Eli Lilly (LLY) Q2 2026 Earnings Call Transcript
Eli Lilly’s Q2 2026 earnings call said revenue rose 48% vs Q2 2025, driven by Zepbound and Mounjaro. Gross margin was 86.3%. Non-GAAP EPS was $8.38. Lilly reported regulatory progress for Foundayo and approvals for Ebglyss, Jaypirca, and Onswik, plus Phase 3 retatrutide results. Dividends were $1.5B and buybacks $1.6B.
How this was made
The 30-second read
Why it matters
Traders can use the disclosed financial metrics and the specific regulatory and launch timeline for Foundayo and other products to update near-term expectations for revenue mix, market share, and margin trajectory.
Market read
The transcript provides a bundle of actionable datapoints: strong Q2 financials, multiple regulatory approvals/opinions, Foundayo expansion progress, and a Medicare access program that can accelerate obesity medicine uptake.
What to watch
Regulatory review timing for Foundayo in many countries and the pace of DTC marketing effectiveness could create volatility; also, large R&D and marketing spend increases may weigh on future profitability if uptake underperforms.
Background
This is a Q2 2026 earnings call transcript covering financial performance, product launches, regulatory milestones, pipeline updates, and capital returns.
Ticker impact
Eli Lilly’s Q2 call discloses 48% revenue growth, 86.3% gross margin, and updates on Foundayo, Ebglyss, Jaypirca, and Onswik approvals.
Bias toward upside as investors price in expanding GLP-1 and obesity access plus incremental approvals and strong prescription momentum.
Multiple concrete catalysts are cited (Foundayo submissions and approvals, FDA/EU/CHMP milestones, Phase 3 retatrutide topline results, and large buybacks/dividends), but the text is a call transcript and may not contain fully new, market-moving guidance beyond what was already anticipated.
Market effects
Reinforces demand momentum in incretin analogs and broadens competitive read-through for obesity and diabetes GLP-1 franchises.
Highlights strong international growth drivers (Europe, Japan, China, rest of world) that can influence regional biotech/pharma sentiment.
Medicare GLP-1 Bridge program details may affect global payer and access expectations for anti-obesity medicines.
Counterpoint
Despite strong growth, the transcript flags price declines (U.S. price down 3%, or 9% excluding adjustments), which could pressure margins or limit upside if rebate/discount dynamics worsen.
Key entities
- companyEli Lilly
Subject of the earnings call transcript, reporting Q2 financial results and updates across obesity/diabetes and pipeline/regulatory milestones.
- productFoundayo
Lilly’s obesity and type 2 diabetes medicine with U.S. submission, expected regulatory action later this year, and approvals in UAE, Saudi Arabia, and Mexico.
- productEbglyss
FDA-approved for maintenance dosing once every 8 weeks in atopic dermatitis, per the call.
- productJaypirca
EU approval for CLL across all lines of therapy, per the call.
- productOnswik
CHMP positive opinion in the EU for insulin efsitora alfa for type 2 diabetes, per the call.
